Navigation Links
Amylin Pharmaceuticals Reports 2008 Financial Results
Date:1/27/2009

The Company's results for the quarter ended December 31, 2008 include a charge of $54.9 million associated with the Company's restructuring. This charge consists primarily of one-time expenses related to facility leases, including impairments of related tenant improvements and employee termination benefits. Net loss excluding this charge was $49.1 million, or $0.36 per share. Non-GAAP operating loss, excluding non-cash items and the restructuring charge, was $20.2 million for the quarter ended December 31, 2008 compared to $47.0 million for the same period in 2007. Including the restructuring charge, GAAP net loss was $104.1 million, or $0.76 per share, for the quarter ended December 31, 2008, compared to $76.9 million, or $0.57 per share, for the same period in 2007.

Fourth quarter highlights

Highlights of Amylin's fourth quarter and recent activities include:

BYETTA

  • Communicated the addition of BYETTA to the American Diabetes Association's treatment guidelines for the medical management of type 2 diabetes.

Exenatide Once Weekly

  • Announced that the ongoing extension of the DURATION-1 study is appropriate to use as the basis for demonstrating comparability between intermediate-scale clinical trial material made in Alkermes' manufacturing facility, and commercial-scale drug product made at Amylin's manufacturing facility based on feedback from the U.S. Food and Drug Administration (FDA).
  • Reaffirmed plans for exenatide once weekly NDA submission to the FDA by the end of the first half of 2009.
  • Completed enrollment of DURATION-3, the third in a planned program of superiority clinical studies of exenatide once weekly, comparing exenatide once weekly to insulin glargine in patients using oral diabetes medications. Results from this study are expected in the t
    '/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine news :

1. Amylin Pharmaceuticals to Webcast Year-End Results
2. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
3. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
4. Amylin Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference
5. Lilly and Amylin Set Date and Time for Conference Call
6. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
7. Amylin Pharmaceuticals Reports First Quarter Financial Results
8. Amylin Pharmaceuticals Reports 2007 Financial Results
9. Xenome Enters Into Joint Research Collaboration to Discover Novel Peptide Therapeutics with Amylin Pharmaceuticals
10. Amylin Pharmaceuticals to Present at Research & Development Day
11. Amylin Pharmaceuticals to Webcast Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... In a continuing effort to remain ... Per Wickstrom, the founder of Choices Recovery in South ... “Salute to the Oscars” celebration held on February ... floor of the luxurious Beverly Hilton Hotel. , ... sustainable product placement in TV and film, this daylong ...
(Date:5/4/2015)... York (PRWEB) May 04, 2015 Takeda ... $2.4 billion to settle thousands of Actos lawsuits ( ... medication increases the risk that a patient will develop ... April 28th, if 95% of those eligible for the ... nearly 9,000 bladder cancer cases currently pending in courts ...
(Date:5/4/2015)... SAN DIEGO, California (PRWEB) May 04, 2015 ... health plans to manage their health is critical to ... patient satisfaction and reducing costs, but this will require ... spectrum. This change also demands that health systems move ... to speakers who took part in the third live ...
(Date:5/4/2015)... 2015 TROY Healthcare Solutions is proud ... Regional User Group (RUG) Conference in Baltimore, MD from ... Regional User Group provides an opportunity for clients to ... exhibitor gallery. , In addition to sponsoring the event, ... North Atlantic RUG Conference. Attendees can stop by the ...
(Date:5/4/2015)... 04, 2015 The opportunity for children to ... are the motivating forces behind The Fairy Godmother Next Door, ... author Amy L. Stark. , The inspiration for the enchanting ... door comes from Stark’s desire to be a fairy godmother. ... fairy godmother to my neighbors’ children since they were born. ...
Breaking Medicine News(10 mins):Health News:Per Wickstrom Interviews TV and Film Star Carolyn Hennesy About Substance Abuse and Treatment 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 2Health News:Actos Lawsuit Settlement: Takeda Pharmaceutical Co. to Pay As Much As $2.4 Billion to Resolve Claims Alleging Actos Causes Bladder Cancer 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 2Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 3Health News:AJMC’s ACO Coalition Explores the New Rules of Patient Engagement 4Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:Introducing New Children’s Book The Fairy Godmother Next Door 2
... Initiative (WHI) report show that hormone therapy is associated with ... well as an increased risk of developing invasive breast cancer ... and preventive medicine at the University at Buffalo and one ... JAMA , says the breast cancers found in these ...
... a little-known variety of the grain that is the ... help soothe the inflammation involved in allergies, asthma, and other ... Agricultural and Food Chemistry . Mendel Friedman and colleagues ... benefits of eating black rice bran. Bran is the outer ...
... HealthDay Reporter , TUESDAY, Oct. 19 (HealthDay News) ... (CML) who decided to stop taking the cancer drug Gleevec ... The study, published online Oct. 19 in The ... that the drug might go beyond long-term cancer control and ...
... Jordan, 20 October 2010 Elsevier Middle East announces ... ( JIPH ) has been selected for inclusion in MEDLINE, ... Medicine (NLM). Citations for articles indexed, the indexing terms and ... PubMed ( www.pubmed.gov ). Indexing using the US National Library ...
... HealthDay Reporter , TUESDAY, Oct. 19 (HealthDay News) -- Not only ... breast cancer, new research finds, but it also ups the risk ... chances of dying. A study appearing in the Oct. 20 ... is at odds with previous observational studies that had suggested a ...
... TUESDAY, Oct. 19 (HealthDay News) -- Heavy alcohol and marijuana ... persist into adulthood, according to a new study. The ... scored lower than their abstinent peers on tests measuring a ... professor of psychiatry at the University of New Mexico School ...
Cached Medicine News:Health News:Hormone therapy increases invasive breast cancer and mortality, WHI 11-year follow up finds 2Health News:Some With Once-Deadly Leukemia Can Take a Break From Gleevec 2Health News:Some With Once-Deadly Leukemia Can Take a Break From Gleevec 3Health News:Study Shows HRT Even Riskier Than Thought 2Health News:Study Shows HRT Even Riskier Than Thought 3Health News:Binge Drinking, Pot Could Put Teens' Intellect at Risk: Study 2Health News:Binge Drinking, Pot Could Put Teens' Intellect at Risk: Study 3
(Date:5/4/2015)... 4, 2015 Southfield Capital, a ... announced today that it completed a dividend ... specializes in the development and multi-channel deployment ... and biotechnology industries. Through the ... half of their invested capital and secured ...
(Date:5/4/2015)... RadiologyAuction will have their first auction starting May ... at the end of the auction on May 27 ... Fuji Cr,s, Agfa and Sony, printers and GE portable ... imaging equipment will be available at later auctions each ... of buying and selling imaging equipment, the brokers at ...
(Date:5/4/2015)... VALLEY, Calif. , May 4, 2015 ... biologic for psoriasis, today announced that preclinical and mechanism ... session at the Society of Investigative Dermatology (SID) Annual ... Atlanta, in Atlanta, Georgia . ... is advancing the development of RON2315, a novel, low ...
Breaking Medicine Technology:Southfield Capital and BioPharm Communications Announce Dividend Recapitalization 2RadiologyAuction Announces Event Starting On May 5th 2Rogne Bioscience to Present Data from Topical Biologic Psoriasis Program at Upcoming SID Annual Meeting 2015 2
... 25, 2007 - Reata,Pharmaceuticals, Inc. today announced ... company's Synthetic Triterpenoid programs in,the May 2007 ... The article, "Triterpenoids and rexinoids as multifunctional,agents ... by researchers,and Reata scientific collaborators from the ...
... - Introgen,Therapeutics, Inc. (NASDAQ:INGN) today announced the publication ... survival,pathway impacts the anticancer activity of INGN 241. ... tumor killing effects of,INGN 241 in cell culture ... Introgen and The University of Texas M. D. ...
Cached Medicine Technology:Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 2Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 3Reata's Synthetic Triterpenoids Profiled in Nature Reviews Cancer 4Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 2Preclinical Studies Identify Novel Approach for Enhancing the,Anticancer Activity of Introgen's INGN 241 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: